ES476496A1 - Procedimiento para preparar derivados de acido ftalazin-4- ilacetico. - Google Patents

Procedimiento para preparar derivados de acido ftalazin-4- ilacetico.

Info

Publication number
ES476496A1
ES476496A1 ES476496A ES476496A ES476496A1 ES 476496 A1 ES476496 A1 ES 476496A1 ES 476496 A ES476496 A ES 476496A ES 476496 A ES476496 A ES 476496A ES 476496 A1 ES476496 A1 ES 476496A1
Authority
ES
Spain
Prior art keywords
formula
radical
compound
hydrogen
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES476496A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imperial Chemical Industries Ltd
Original Assignee
Imperial Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Chemical Industries Ltd filed Critical Imperial Chemical Industries Ltd
Publication of ES476496A1 publication Critical patent/ES476496A1/es
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30Phthalazines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30Phthalazines
    • C07D237/32Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Procedimiento para preparar derivados de ácido ftalazin-4-ilacético , de fórmula:**fórmula**, donde R1 es un radical hidroxi o benciloxi, o un radical acolxi C1-4 portando opcionalmente un radical N-morfolino o dialquilamino C1-4; y los sustituyentes R2, R3, R4 y R5 en el anillo de benceno A son seleccionados a partir de cualquiera de las siguientes combinaciones: a) R2 es un radical fluor o metoxi , R3 es hidrógeno, R4 es un radical cloro, bromo o yodo, y R5 es hidrógeno o un radical halógeno; b) R2,R3 y R5 son hidrógeno, y R4 es un radical bromo o yodo c) R2 es hidrógeno o un radical flúor, R3 y R5 son iguales o distintos radicales halógeno, y R4 es hidrógeno; d) R2 es hidrógeno o un radical fluor, R3 y R4 son iguales o distintos radicales halógeno, y R5 es hidrógeno; y e) R2 es hidrógeno, R3 y R5 son, independientemente, radicales flúor o cloro, y R4 es un radical cloro, bromo o yodo; y donde e, en el anillo de benceno B, R6,R7 y R8 son seleccionados independientemente entre hidrógeno, halógeno y radicales alquilo C1-4 y alcoxi C1-4, o bien R6 y R7 juntos constituyen un radical bivalente alquilenoxidioxi; a condición de que por lo menos uno de R6,R7 y R8 sea hidrógeno; y X es oxígeno o azufre, o una sal básica de adición farmaceúticamente aceptable de un compuesto de la fórmula I dónde R1 es un radical hidroxi, o una sal ácida de adición farmaceuticamente aceptable de un compuesto de la fórmula I donde R1 es un radical alcoxi C1-4, portando un radical N-morfolino o dialquilamino C1-4; caracterizado porque comprende: a) para un compuesto de fórmula I donde X es oxígeno, reaccionar un compuesto de fórmula: **fórmula** con haluro de fórmula **fórmula** donde Hal es un radical cloro, bromo o yodo, en presencia de una base apropiada; b) para un compuesto de la fórmula I donde R1 es un radical hidroxi, hidrolizar un éster de fórmula: **fórmula** donde R9 es un radical alcoxi C1-4 ó un radical de fórmula: **fórmula** c) para un compuesto de la fórmula I donde X es oxígeno, reaccionar un compuesto de fórmula: **fórmula** o un isómero geométrico del mismo, con una hidrazina de fórmula ** fórmula** d) para un compuesto de la fórmula I donde X es oxígeno y R1 es un radical hidroxi o un radical alcoxi C1-4, descomponer por catálisis una diazocetona de fórmula: fórmula en presencia de un compuesto de la fórmula Q.H, donde Q es un radical hidroxi o alcoxi C1-4; e) para un compuesto de la fórmula I donde R1 es un radical hidroxi, descarboxilar un ácido malónico de la siguiente fórmula: **fórmula** f) para un compuesto de la fórmula I donde el anillo de benceno B porta un radical alcoxi C1-4, reaccionar un compuesto de la fórmula I donde el anillo benceno B porta un radical halógeno con un alcóxido C1-4 metálico alcalino; y luego , cuando se requiere un compuesto de la fórmula I donde R1 no es un radical hidroxi, un compuesto de la fórmula I donde R1 es un radical hidroxi o un derivado reactivo del mismo, se hace reaccionar con un compuesto de la fórmula R10.H, donde R10 tiene el mismo significado que R1 que no sea una radical hidroxi, usando procedimientos de esterificación conocidos, y cuando se requiere un compuesto de la fórmula I donde X es azufre, un compuesto de la fórmula I donde X es oxígeno, se sulfura por los procedimientos de sulfuración conocidos, y cuando se requiere una sal farmacéuticamente aceptable, se hace reaccionar un compuesto de la fórmula I, donde R1 es un radical hidroxi, con una base que ofrezca un catión farmacéuticamente aceptable, o se hace reaccionar un compuesto de la fórmula I, donde R1 es un radical alcoxi C1-4 portando un radical N-mormolino o di-N,N-alquilamino C1-4 con un ácido que ofrezca un anión farmacéuticamente aceptable, y donde X , los anillos de benceno A y B, y los sustituyentes en los mismos, tienen cualquiera de los significados definidos anteriormente.
ES476496A 1977-12-29 1978-12-29 Procedimiento para preparar derivados de acido ftalazin-4- ilacetico. Expired ES476496A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB5414277 1977-12-29

Publications (1)

Publication Number Publication Date
ES476496A1 true ES476496A1 (es) 1979-04-16

Family

ID=10470067

Family Applications (1)

Application Number Title Priority Date Filing Date
ES476496A Expired ES476496A1 (es) 1977-12-29 1978-12-29 Procedimiento para preparar derivados de acido ftalazin-4- ilacetico.

Country Status (31)

Country Link
US (2) US4251528A (es)
EP (1) EP0002895B1 (es)
JP (2) JPS5495582A (es)
AT (1) AT365581B (es)
AU (1) AU516264B2 (es)
BG (1) BG34336A3 (es)
CA (1) CA1107732A (es)
CS (1) CS241015B2 (es)
CY (1) CY1219A (es)
DD (1) DD141021A5 (es)
DE (1) DE2861170D1 (es)
DK (1) DK151253C (es)
ES (1) ES476496A1 (es)
FI (1) FI64357C (es)
GR (1) GR65303B (es)
HK (1) HK22484A (es)
HU (1) HU182585B (es)
IE (1) IE47592B1 (es)
IL (1) IL56099A0 (es)
IN (1) IN150196B (es)
IT (1) IT1110885B (es)
MY (1) MY8500359A (es)
NO (1) NO154346C (es)
NZ (1) NZ189034A (es)
PH (1) PH15435A (es)
PL (1) PL118443B1 (es)
PT (1) PT68956A (es)
SG (1) SG68683G (es)
SU (3) SU1087075A3 (es)
YU (3) YU41607B (es)
ZW (1) ZW24978A1 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
CA1143733A (en) * 1979-07-31 1983-03-29 Masao Yoshida Producing 7-alkoxycarbonyl-6,8-dimethyl-4- hydroxymethyl-1-phthalazone and intermediates
US4762839A (en) * 1985-06-06 1988-08-09 Tanabe Seiyaku Co., Ltd. Quinazolinone copmpounds useful for the prophyloxis and treatment of diabetic complications
ES2032749T3 (es) * 1985-11-07 1993-03-01 Pfizer Inc. Acidos oxoftalazinil-aceticos heterociclicos.
JPS63132889A (ja) * 1986-11-21 1988-06-04 Tanabe Seiyaku Co Ltd キナゾリノン誘導体
US5011840A (en) * 1986-11-24 1991-04-30 Pfizer Inc. Imidazolidinedione derivatives in diabetes treatment
GB8704569D0 (en) * 1987-02-26 1987-04-01 Ici America Inc Therapeutic agent
US4868301A (en) * 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
JPH0676391B2 (ja) * 1987-06-09 1994-09-28 フアイザー・インコーポレイテツド ベンゾチアゾール等の複素環側鎖を有するオキソフタラジニル酢酸類の製造方法
IL88150A0 (en) * 1987-11-02 1989-06-30 Merck & Co Inc Pharmaceutical tablet compositions containing phthalizine acetic acid compounds
DK607188A (da) * 1987-11-02 1989-06-22 Merck & Co Inc Tablet indeholdende en phthalazineddikesyreforbindelse
US4880928A (en) * 1987-12-21 1989-11-14 Merck & Co., Inc. Process for the preparation of 3-((4-bromo-2-fluorophenyl)methyl)-3,4-dihydro-4-oxo-1-phthalazine-acetic acid
US4940791A (en) * 1988-02-29 1990-07-10 Pfizer Inc. Process for the production of phthalazineacetic acid ester derivatives and a novel hydrazine containing intermediate
US4904782A (en) * 1988-02-29 1990-02-27 Pfizer Inc. Process for the production of phthalazineacetic acid ester derivatives and a novel intermediate
US4954629A (en) * 1989-05-11 1990-09-04 Pfizer Inc. Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
US4996204A (en) * 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
EP0397930A1 (en) * 1989-05-18 1990-11-22 Merck & Co. Inc. Process for the preparation of 3-[(4-bromo-2-fluorophenyl) methyl]-3,4-dihydro-4-oxo-1-phthalazineacetic acid
FR2647676A1 (fr) * 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
US5304557A (en) * 1989-12-15 1994-04-19 Pfizer Inc. Substituted oxoophthalazinyl acetic acids and analogs thereof
US5037831A (en) * 1990-05-21 1991-08-06 American Home Products Corporation Spiro-isoquinoline-pyrrolidines and analogs thereof useful as aldose reductase inhibitors
FR2682108B1 (fr) * 1991-10-07 1994-01-07 Lipha Acide 3,4-dihydro-4-oxo-3(prop-2-enyl)-1-phtalazineacetiques et derives, leurs preparations et medicaments les contenant.
NZ254550A (en) * 1992-09-28 1997-08-22 Pfizer Use of nitrogen-substituted pyrimidines to prepare medicaments useful for treatment or prevention of diabetic complications
JPH08502973A (ja) * 1992-11-02 1996-04-02 メルク エンド カンパニー インコーポレーテッド ニューロテンシンアンタゴニストとしての置換フタラジノン
CH683965A5 (it) * 1993-02-19 1994-06-30 Limad Marketing Exp & Imp Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici.
JPH09506068A (ja) * 1993-07-26 1997-06-17 藤沢薬品工業株式会社 悪液質治療のためのオキソフタラジン類
US6696407B1 (en) 1997-03-21 2004-02-24 The Regents Of The University Of California Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
AU6473898A (en) * 1997-03-21 1998-10-20 Regents Of The University Of California, The Methods for modulating neurotrophic factor-associated activity using aldose reductase inhibitors
ATE422359T1 (de) * 1997-04-15 2009-02-15 Csir Verbindungen und pharmazeutische zusammensetzungen mit appetitunterdrückender aktivität
SK7522001A3 (en) * 1998-03-31 2002-02-05 Inst For Pharm Discovery Inc Substituted indolealkanoic acids
TNSN99224A1 (fr) 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
GB2396815B (en) * 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
DE19963607B4 (de) * 1999-12-23 2005-12-15 Schering Ag Verfahren zur Herstellung von 4-(Heteroaryl-methyl) halogen-1(2H)-phthalazinonen
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
HRP20030419A2 (en) * 2000-11-30 2004-08-31 Pfizer Prod Inc Combination of gaba agonists and aldose reductase inhibitors
ES2240657T3 (es) 2001-02-28 2005-10-16 Pfizer Products Inc. Compuestos de sulfonilpiridazinona utiles como inhibidores de aldosa reductasa.
ATE348100T1 (de) * 2001-03-30 2007-01-15 Pfizer Prod Inc Zwischenprodukten für die herstellung von pyridazinon aldose reductase inhibitoren.
AU2002236131B2 (en) * 2001-04-30 2005-04-14 Pfizer Products Inc. Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors
AU761191B2 (en) 2001-05-24 2003-05-29 Pfizer Products Inc. Therapies for tissue damage resulting from ischemia
WO2003092696A1 (en) * 2002-04-30 2003-11-13 Novartis Ag Method for decreasing capillary permeability in the retina
KR20050026002A (ko) * 2002-07-26 2005-03-14 디 인스티튜트스 포 파마슈티컬 디스커버리, 엘엘씨 치환된 인돌알칸산 유도체 및 이를 함유하는 당뇨 합병증치료용 제형
US7572910B2 (en) * 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
JP4838582B2 (ja) * 2004-12-27 2011-12-14 岐阜プラスチック工業株式会社 台車用本体
ATE518544T1 (de) 2007-03-12 2011-08-15 Zadec Aps Rotbusch-extrakt gegen diabetes
CA2685202C (en) 2007-03-23 2017-11-28 The Board Of Regents Of The University Of Texas System Methods for treating allergic asthma
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
CA2822672C (en) 2010-12-23 2018-06-05 The Board Of Regents Of The University Of Texas System Methods for treating copd
WO2014093988A2 (en) * 2012-12-14 2014-06-19 Phusis Therapeutics, Inc. Methods and compositions for inhibiting cnksr1
US10227356B2 (en) 2015-04-20 2019-03-12 Phusis Therapeutics, Inc. Compounds, compositions and methods for inhibiting CNKSR1
US12090142B2 (en) 2018-02-22 2024-09-17 Board Of Regents, The University Of Texas System Combination therapy for the treatment of cancer
JP6936290B2 (ja) * 2018-10-04 2021-09-15 日東電工株式会社 耐熱離型シート及び熱圧着方法
JP6751974B1 (ja) * 2019-10-16 2020-09-09 株式会社コバヤシ 離型フィルム及び離型フィルムの製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3833579A (en) * 1935-11-11 1974-09-03 Inoue Michiro 4-carbamoyl phthalazones
JPS5116430B2 (es) * 1971-08-05 1976-05-24
GB1398549A (en) * 1972-11-06 1975-06-25 Boots Co Ltd Phthalazine derivatives and their use in pharmaceutical compo sitions
AR205004A1 (es) * 1973-10-30 1976-03-31 Ishikawa M Procedimiento para preparar derivados de 6,8-dialquil-7-alcoxi-carbonil-4-hidroximetil-1-ftalazona y la 7,8-lactona
DE2451117A1 (de) * 1973-10-31 1975-05-22 Boots Co Ltd Therapeutisch wirksame verbindungen
GB1502312A (en) 1975-03-20 1978-03-01 Ici Ltd Quinolone derivatives
IE43079B1 (en) * 1975-03-20 1980-12-17 Ici Ltd Quinolone derivatives
JPS5214788A (en) * 1975-07-21 1977-02-03 Fuji Photo Film Co Ltd Process for preparing phthalazinone and its derivatives
NL7702763A (nl) * 1976-03-18 1977-09-20 Takio Shimamoto En Masayuki Is Werkwijze voor de bereiding van thromboxaan- -antagonisten en van preparaten die deze stof- fen bevatten.
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
US4293553A (en) * 1978-08-11 1981-10-06 Masayuki Ishikawa 1-Phthalazone derivatives, and use thereof

Also Published As

Publication number Publication date
AT365581B (de) 1982-01-25
NZ189034A (en) 1981-11-19
SG68683G (en) 1984-08-03
CA1107732A (en) 1981-08-25
DK151253B (da) 1987-11-16
IN150196B (es) 1982-08-14
AU516264B2 (en) 1981-05-28
NO154346B (no) 1986-05-26
ZW24978A1 (en) 1980-10-22
EP0002895B1 (en) 1981-10-14
YU232082A (en) 1983-01-21
SU1087075A3 (ru) 1984-04-15
US4393062A (en) 1983-07-12
SU1272984A3 (ru) 1986-11-23
PL118443B1 (en) 1981-10-31
GR65303B (en) 1980-08-01
DK541878A (da) 1979-06-30
IE782337L (en) 1979-06-29
IT7852480A0 (it) 1978-12-28
PT68956A (en) 1979-01-01
FI783844A7 (fi) 1979-06-30
FI64357B (fi) 1983-07-29
DD141021A5 (de) 1980-04-09
NO154346C (no) 1986-09-03
YU41607B (en) 1987-12-31
AU4204078A (en) 1979-07-05
HK22484A (en) 1984-03-23
BG34336A3 (bg) 1983-08-15
ATA937678A (de) 1981-06-15
PH15435A (en) 1983-01-18
JPS5495582A (en) 1979-07-28
YU232182A (en) 1983-01-21
IL56099A0 (en) 1979-01-31
FI64357C (fi) 1983-11-10
DK151253C (da) 1988-05-16
IT1110885B (it) 1986-01-06
SU1072803A3 (ru) 1984-02-07
HU182585B (en) 1984-02-28
CY1219A (en) 1984-04-06
YU42807B (en) 1988-12-31
CS241015B2 (en) 1986-03-13
YU42054B (en) 1988-04-30
US4251528A (en) 1981-02-17
JPS6326110B2 (es) 1988-05-27
DE2861170D1 (en) 1981-12-24
EP0002895A1 (en) 1979-07-11
MY8500359A (en) 1985-12-31
JPH0262532B2 (es) 1990-12-26
IE47592B1 (en) 1984-05-02
NO784397L (no) 1979-07-02
JPS63119469A (ja) 1988-05-24
YU312778A (en) 1983-01-21

Similar Documents

Publication Publication Date Title
ES477695A1 (es) Un procedimiento para preparar derivados de deshidrociclici-minoacidos.
SE7603931L (sv) Forfarande for framstellning av nya tetracykliska foreningar
ES8601924A1 (es) Un procedimiento para la preparacion de nuevas 2-amino-5-hidroxi-4-metilpirimidinas.
ES485274A1 (es) Un procedimiento para la preparacion de derivados de fenil- piperacina
ES8706606A1 (es) Un procedimiento para preparar aril-hidroxamatos
GB925429A (en) Indole derivatives
ES8201116A1 (es) Procedimiento para preparar derivados de 2-nitro-5-(fenoxi sustituido)-benzoilo
WO1979001114A1 (fr) Dialkyl 4-methylphosphinobutyrates et leur procede de fabrication
GB1461173A (en) Preparation of 3- 4-or 5-substituted thiazol-2-oxy- propanediol 1,2-acetonides
OA06585A (fr) Dérivés triazonyl-alcéniques, leur procédé de production et leur utilisation comme fongicides.
ES2060250T3 (es) Procedimiento para producir beta-caroteno y compuestos intermedios utiles para el procedimiento.
AU568064B2 (en) 4-acylamino-1-aza-adamantanes
IE792300L (en) 2,4, 6-triiodoisophthalamic acid derivatives; x-ray¹contrast agents
ES8301888A1 (es) "procedimiento para la preparacion de derivados de fenoxi-aminopropanol substituidos" como divisional de la patente de invencion n 502.649 del 1 junio 1981.
FR2474488B1 (es)
GB1082072A (en) Phenylsulfinylalkanoic acid derivatives
ES459087A1 (es) Procedimiento para preparar fenilacetilenos sustituidos.
GB2005267A (en) Indole derivatives their preparation and pharmaceutical compositions containing them
GB2004543A (en) A process for preparing phenylalkane carboxylic acids
ES8603412A1 (es) Procedimiento para la obtencion de acemetacina
FR2383184A1 (fr) Procede de preparation d'ethers
ES8600188A1 (es) Procedimiento de preparacion de un derivado 1,1-difenilpropan-1-ol
SE8204791D0 (sv) Process for preparing alkoxy-vincaminic acid esters and alkoxy-apovincaminic acid esters
ES471193A1 (es) Procedimiento para la preparacion de derivados pirazolinicos
JPS5265251A (en) Synthesis of prostaglandin derivatives

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20000301